BACKGROUND: Statins compete with DHEAS for influx through the SLCO2B1 transporter, which may prolong time to progression (TTP) on androgen deprivation therapy. Abiraterone acetate (AA) may also undergo SLCO-mediated transport. Based on preclinical findings showing antagonism, we hypothesized that statins may compete with AA for influx via SLCO2B1 and could negatively impact drug efficacy. METHODS: We queried two institutional clinical databases (Dana-Farber Cancer Institute [DFCI], Johns Hopkins University [JHU]) for CRPC patients treated with AA. Treatment duration was a surrogate for TTP. Associations between statin use and AA duration were estimated using the Kaplan-Meier method. Multivariable Cox regression modeling adjusted for known prognostic factors. RESULTS: Of the 224 DFCI and 270 JHU patients included, the majority (96%) had metastatic disease. Nearly half (41% and 45%) were statin users. In the DFCI cohort, there was a trend toward longer AA duration in statin users: 14.2 versus 9.2 months (HR 0.79, 95%CI: 0.57-1.09, P = 0.14). There was no association between statin use and AA duration in the JHU cohort: 8.3 versus 8.0 months (HR 0.89, 95%CI: 0.69-1.16, P = 0.38) in the statin users versus non-users, except for a trend in patients that had not previously received docetaxel or enzalutamide (HR 0.79; 95%CI: 0.57-1.10). CONCLUSIONS: Contrary to our initial hypothesis, there was a trend toward longer (rather than shorter) AA duration in statin users in the entire DFCI cohort and in the enzalutamide- and docetaxel-naïve JHU patients. Together, these results do not support the hypothesis that statins interfere with AA efficacy.
BACKGROUND: Statins compete with DHEAS for influx through the SLCO2B1 transporter, which may prolong time to progression (TTP) on androgen deprivation therapy. Abiraterone acetate (AA) may also undergo SLCO-mediated transport. Based on preclinical findings showing antagonism, we hypothesized that statins may compete with AA for influx via SLCO2B1 and could negatively impact drug efficacy. METHODS: We queried two institutional clinical databases (Dana-Farber Cancer Institute [DFCI], Johns Hopkins University [JHU]) for CRPC patients treated with AA. Treatment duration was a surrogate for TTP. Associations between statin use and AA duration were estimated using the Kaplan-Meier method. Multivariable Cox regression modeling adjusted for known prognostic factors. RESULTS: Of the 224 DFCI and 270 JHU patients included, the majority (96%) had metastatic disease. Nearly half (41% and 45%) were statin users. In the DFCI cohort, there was a trend toward longer AA duration in statin users: 14.2 versus 9.2 months (HR 0.79, 95%CI: 0.57-1.09, P = 0.14). There was no association between statin use and AA duration in the JHU cohort: 8.3 versus 8.0 months (HR 0.89, 95%CI: 0.69-1.16, P = 0.38) in the statin users versus non-users, except for a trend in patients that had not previously received docetaxel or enzalutamide (HR 0.79; 95%CI: 0.57-1.10). CONCLUSIONS: Contrary to our initial hypothesis, there was a trend toward longer (rather than shorter) AA duration in statin users in the entire DFCI cohort and in the enzalutamide- and docetaxel-naïve JHU patients. Together, these results do not support the hypothesis that statins interfere with AA efficacy.
Authors: Mark A Preston; Anders H Riis; Vera Ehrenstein; Rodney H Breau; Julie L Batista; Aria F Olumi; Lorelei A Mucci; Hans-Olov Adami; Henrik T Sørensen Journal: Eur Urol Date: 2014-05-22 Impact factor: 20.096
Authors: Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher Journal: N Engl J Med Date: 2011-05-26 Impact factor: 91.245
Authors: Daniel Tamae; Elahe Mostaghel; Bruce Montgomery; Peter S Nelson; Steven P Balk; Philip W Kantoff; Mary-Ellen Taplin; Trevor M Penning Journal: Chem Biol Interact Date: 2014-12-13 Impact factor: 5.192
Authors: Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf Journal: N Engl J Med Date: 2012-12-10 Impact factor: 91.245
Authors: Johan Monbaliu; Martha Gonzalez; Apexa Bernard; James Jiao; Carlo Sensenhauser; Jan Snoeys; Hans Stieltjes; Inneke Wynant; Johan W Smit; Caly Chien Journal: Drug Metab Dispos Date: 2016-08-08 Impact factor: 3.922
Authors: R Bruce Montgomery; Elahe A Mostaghel; Robert Vessella; David L Hess; Thomas F Kalhorn; Celestia S Higano; Lawrence D True; Peter S Nelson Journal: Cancer Res Date: 2008-06-01 Impact factor: 12.701
Authors: Xiaodong Wang; Lauren C Harshman; Wanling Xie; Mari Nakabayashi; Fangfang Qu; Mark M Pomerantz; Gwo-Shu Mary Lee; Philip W Kantoff Journal: J Clin Oncol Date: 2015-12-14 Impact factor: 44.544
Authors: Martin Boegemann; Katrin Schlack; Ann-Kathrin Fischer; Joachim Gerß; Julie Steinestel; Axel Semjonow; Andres Jan Schrader; Laura-Maria Krabbe Journal: PLoS One Date: 2016-09-01 Impact factor: 3.240
Authors: Jacob A Gordon; Carlo Buonerba; Gregory Pond; Daniel Crona; Silke Gillessen; Giuseppe Lucarelli; Sabrina Rossetti; Tanya Dorff; Salvatore Artale; Jennifer A Locke; Davide Bosso; Matthew Ivan Milowsky; Mira Sofie Witek; Michele Battaglia; Sandro Pignata; Cyrus Cherhroudi; Michael E Cox; Pietro De Placido; Dario Ribera; Aurelius Omlin; Gaetano Buonocore; Kim Chi; Christian Kollmannsberger; Daniel Khalaf; Gaetano Facchini; Guru Sonpavde; Sabino De Placido; Bernhard J Eigl; Giuseppe Di Lorenzo Journal: Oncotarget Date: 2018-04-13
Authors: Giuseppe Fallara; Ingela Franck Lissbrant; Johan Styrke; Francesco Montorsi; Hans Garmo; Pär Stattin Journal: PLoS One Date: 2020-12-28 Impact factor: 3.240
Authors: Juan José Serrano Domingo; Teresa Alonso Gordoa; Javier Lorca Álvaro; Javier Molina-Cerrillo; Arantzazu Barquín García; Olga Martínez Sáez; Javier Burgos Revilla; Alfredo Carrato; Sara Álvarez Rodríguez Journal: Ther Adv Urol Date: 2021-09-17
Authors: Paavo V H Raittinen; Heimo Syvälä; Teuvo L J Tammela; Merja R Häkkinen; Pauliina Ilmonen; Seppo Auriola; Teemu J Murtola Journal: EBioMedicine Date: 2021-06-16 Impact factor: 8.143
Authors: A Auvinen; T J Murtola; A I Peltomaa; P Raittinen; K Talala; K Taari; T L J Tammela Journal: Prostate Cancer Prostatic Dis Date: 2021-03-31 Impact factor: 5.554